Musings from The Power List: John Maher
By John Maher
August 14, 2026
John Maher discusses the scientific and practical challenges of bringing CAR T-cell therapies to patients with solid tumors
4 min read
False
Advertisement
Cell & Gene
Why Cell Therapy Needs a Digital Backbone
August 13, 2026
Alexander Seyf on why the UK is losing ground in cell and gene therapy, the real bottlenecks to commercialization, and why digitalization is no longer optional
8 min read
This Week’s CGT News: In Vivo CAR T Draws Major Investment
August 10, 2026
Johnson & Johnson partners with Sail Biomedicines, an FDA advisory committee votes against deramiocel for Duchenne cardiomyopathy, and researchers uncover factors influencing CAR T and CAR NK outcomes
3 min read
Building Commercial Readiness in Advanced Therapies
August 10, 2026
Why early process development, analytical planning, and tech transfer can shape the future of cell and gene therapy manufacturing
5 min read
This Week’s CGT News: Gene-Editing Trial Death Raises Concerns
August 3, 2026
A previously undisclosed death in China raises questions about gene-editing oversight, deramiocel meets its Phase 3 Duchenne endpoint, and researchers identify a source of CAR NK dysfunction
4 min read
Musings from The Power List: Claudia Zylberberg
July 30, 2026
Claudia Zylberberg discusses building the infrastructure, partnerships, and policies needed to bring advanced therapies to patients at scale
8 min read
This Week’s CGT News: Off-the-Shelf CAR T Tackles Kidney Cancer
July 27, 2026
Allogeneic CAR T produces durable responses in advanced kidney cancer, the FDA clears a CD22-directed in vivo therapy, and Repligen agrees to acquire BioLife Solutions for $1.5 billion
4 min read
Single-Cell Analysis Reveals Hidden CAR T Manufacturing Risks
July 23, 2026
Mission Bio’s Mike Molnar explains how single-cell multiomics could improve vector copy number analysis, product characterization, and safety assessment in CAR T development
5 min read
The Power List 2026 is Live
July 21, 2026
We celebrate 60 inspiring individuals helping turn pharma’s boldest ideas into reality
2 min read
This Week’s CGT News: First-in-Human Diabetes Cell Therapy
July 20, 2026
First-in-human diabetes cell replacement, early iPSC-derived CAR T data in systemic sclerosis, AAV gene therapy for fragile X syndrome, and fresh funding for off-the-shelf CAR T
4 min read
